ApoB100 secretion from HepG2 cells is decreased by the ACAT inhibitor CI-1011: An effect associated with enhanced intracellular degradation of ApoB

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 4, 1999, Pages 939-949

  Wilcox, Lisa J ^a   Barrett, P Hugh R ^b   Newton, Roger S ^c   Huff, Murray W ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WASHINGTON   (United States)

^c PFIZER INC   (United States)

Author keywords

Acyl CoA: cholesterol acyltransferase inhibitor; ApoB; Cholesterol esterification; CI 1011; DuP 128; HepG2 cells

Indexed keywords

APOLIPOPROTEIN B100; CHOLESTEROL; CHOLESTEROL ESTER; SULFAMIC ACID ((2,4,6 TRIS (1 METHYLETHYL) PHENYL)ACETYL) 2,6 BIS(1 METHYLETHYL) PHENYL ESTER; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEPG2; CHOLESTEROL ESTERIFICATION; HUMAN; HUMAN CELL; LIPOGENESIS; LIPOPROTEIN SECRETION; LIVER CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 0032918323     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.4.939     Document Type: Article

References (66)

1. Chan L. Apolipoprotein B, the major protein component of triglyceride rich and low density lipoprotein. J Biol Chem. 1992;267:25621-25624.
2. Sigurdsson G, Nicholl A, Lewis B. Conversion of very low density lipoprotein to low density lipoprotein: a metabolic study of apolipoprotein B catabolism in man. J Clin Invest. 1975;56:1481-1490.
3. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232:34-47.
4. Sakata N, Wu X, Dixon J, Ginsberg HN. Proteolysis and lipid-facilitated translocation are distinct but competitive processes that regulate secretion of apolipoprotein B in HepG2 cells. J Biol Chem. 1993;268: 22967-22970.
5. Du EZ, Kurth J, Wang S, Humiston P, Davis RA. Proteolysis-coupled secretion of the N-terminus of apolipoprotein B. Characterization of a transient, translocation arrested intermediate. J Biol Chem. 1994;269: 24169-24176.
6. Dashti N. The effect of low density lipoproteins, cholesterol, and 25-hydroxycholesterol on apolipoprotein B gene expression in HepG2 cells. J Biol Chem. 1992;267:7160-7169.
7. Wu X, Sakata N, Dixon J, Ginsberg HN. Exogenous VLDL stimulates apolipoprotein B secretion from HepG2 cells by both pre-and posttranslational mechanisms. J Lipid Res. 1994;35:1200-1210.
8. Pullinger CR, North JD, Teng B, Rifici VA, Ronhild de Brito AE, Scott J. The apolipoprotein B gene is constitutively expressed in HepG2 cells: regulation of secretion by oleic acid, albumin, and insulin, and measurement of the mRNA half-life. J Lipid Res. 1989;30:1065-1077.
9. Zhang Z, Sniderman AD, Kalant D, Vu H, Monge JC, Tao Y, Cianflone K. The role of amino acids in apoB100 synthesis and catabolism in human HepG2 cells. J Biol Chem. 1993;268:26920-26926.
10. Sniderman AD, Cianflone K. Substrate delivery as a determinant of hepatic apoB secretion. Arterioscler Thromb. 1993;13:629-636.
11. Dixon J, Ginsberg HN. Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: information obtained from cultured liver cells. J Lipid Res. 1993;34:167-179.
12. Dixon J, Furukawa S, Ginsberg HN. Oleate stimulates secretion of apolipoprotein B-containing lipoproteins from HepG2 cells by inhibiting early intracellular degradation of apolipoprotein B. J Biol Chem. 1991; 266:5080-5086.
13. Furukawa S, Hirano T. Rapid stimulation of apolipoprotein B secretion by oleate is not associated with cholesteryl ester biosynthesis in HepG2 cells. Biochim Biophys Acta. 1993;1170:32-37.
14. Wu X, Sakata N, Lui E, Ginsberg HN. Evidence for a lack of regulation of the assembly and secretion of apolipoprotein B-containing lipoprotein from HepG2 cells by cholesteryl ester. J Biol Chem. 1994;269: 12375-12382.
15. Benoist F, Grand-Perret T. ApoB-100 secretion by HepG2 cells is regulated by the rate of triglyceride biosynthesis but not by intracellular lipid pools. Arterioscler Thromb Vasc Biol. 1996;16:1229-1235.
16. Yao Z, Vance DE. The active synthesis of phosphatidylcholine is required for very low density lipoprotein secretion from rat hepatocytes. J Biol Chem. 1988;263:2998-3004.
17. Musanti R, Giorgini L, Lovisolo P, Pirillo A, Chiari A, Ghiselli G. Inhibition of acyl-CoA:cholesterol acyltransferase decreases apolipoprotein B-100-containing lipoprotein secretion from HepG2 cells. J Lipid Res. 1996;37:1-14.
18. Tanaka M, Jingami H, Otani H, Cho M, Ueda Y, Arai H, Nagano Y, Doi T, Yokode M, Kita T. Regulation of apolipoprotein B production and secretion in response to the change of intracellular cholesteryl ester contents in rabbit hepatocytes. J Biol Chem. 1993;268:12713-12718.
19. Cianflone K, Yasruel Z, Rodriguez MA, Vas D, Sniderman AD. Regulation of apoB secretion from HepG2 cells: evidence for a critical role for cholesteryl ester synthesis in the response to a fatty acid challenge. J Lipid Res. 1990;31:2045-2055.
20. Kohen Avramoglu R, Cianflone K, Sniderman AD. Role of the neutral lipid accessible pool in the regulation of secretion of apoB-100 lipoprotein particles by HepG2 cells. J Lipid Res. 1995;36:2513-2528.
21. Qin W, Infante J, Wang S, Infante R. Regulation of HMG-CoA reductase, apolipoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in HepG2, human and rat hepatocytes. Biochim Biophys Acta. 1992;1127:57-66.
22. Carr TP, Hamilton JRL, Rudel LL. ACAT inhibitors decrease secretion of cholesteryl esters and apolipoprotein B by perfused livers of African green monkeys. J Lipid Res. 1995;36:25-36.
23. Huff MW, Telford DE, Barrett PH, Bilheimer DW, Gillies PJ. Inhibition of hepatic ACAT decreases apoB secretion in miniature pigs fed a cholesterol-free diet. Arterioscler Thromb. 1994;14:1498-1508.
24. Arad Y, Ramakrishnan R, Ginsberg HN. Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism. 1992;41:487-493.
25. Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PHR, Newton RS, Huff MW. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs. Arterioscler Thromb Vasc Biol. 1997;17:2589-2600.
26. Sato R, Imanaka T, Takano T. The effect of HMG-CoA reductase inhibitor (CS-514) on the synthesis and secretion of apolipoproteins B and A-1 in the human hepatoblastoma HepG2. Biochim Biophys Acta. 1990;1042: 36-41.
27. Shaw MK, Newton RS, Sliskovic DR, Roth BD, Ferguson E, Krause BR. HepG2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase. Biochem Biophys Res Commun. 1990; 170:726-734.
28. Lee HT, Sliskovic DR, Picard JA, Roth BD, Wieranga W, Hicks JL, Bousley RF, Hamelehle KL, Homan R, Speyer C, Stanfield RL, Krause BR. Inhibitors of acyl-CoA:cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets. J Med Chem. 1996;39:5031-5034.
29. Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Huff MW. Inhibition of cholesterol esterification by DuP 128 decreases hepatic apolipoprotein B secretion in vivo: effect of dietary fat and cholesterol. Biochim Biophys Acta. 1998;1393:63-79.
30. Krause BR, Pape ME, Rea T, Bousley R, Stanfield R, Kieft K, Anderson MK, Lee H, Homan R. CI-1011: a novel cholesterol-lowering compound in both chow-fed and cholesterol-fed rodent and nonrodent species. XII International Symposium on Drugs Affecting Lipid Metabolism. 1995;136. Abstract.
31. Auerbach B, Bousley R, Stanfield R, Bisgaier CL, Homan R, Krause BR. Modulation of apoB kinetics and lipoprotein cholesterol in the casein-fed rabbit by CI-1011: in vivo evidence for liver ACAT inhibition. XII International Symposium on Drugs Affecting Lipid Metabolism. 1995;135. Abstract.
32. Lee HT, Picard JA, Sliskovic DR, Roth BD, Hamelehle KL, Bousley R, Krause BR, Stanfield R. CI-1011: A potent lipid regulating agent. XII International Symposium on Drugs Affecting Lipid Metabolism. 1995;101. Abstract.
33. Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PHR, Newton RS, Huff MW. Hepatic apolipoprotein B secretion, in vivo, is decreased by the ACAT inhibitor CI-1011 in miniature pigs. Circulation. 1997;S96: I-544. Abstract.
34. Evans AJ, Sawyez CG, Wolfe BM, Huff MW. Lipolysis is a prerequisite for lipid accumulation in HepG2 cells induced by large hypertriglyceridemic very low density lipoproteins. J Biol Chem. 1992;267: 10743-10751.
35. Markwell MK, Haas SM, Tolbert NE. A modification of the lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem. 1978;87:206-210.
36. Carr TP, Andresen CJ, Rudel LL. Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts. Biochemistry. 1993;26:39-42.
37. Whitman SC, Sawyez CG, Miller DB, Wolfe BM, Huff MW. Oxidized type IV hypertriglyceridemic VLDL-remnants cause greater macrophage cholesteryl ester accumulation than oxidized LDL. J Lipid Res. 1998;39: 1008-1020.
38. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957; 226:497-509.
39. Huff MW, Telford DE, Woodcraft K, Strong WLP. Mevinolin and cholestyramine inhibit the direct synthesis of low density lipoprotein apolipoprotein B in miniature pigs. J Lipid Res. 1985;26:1175-1186.
40. Egusa G, Brady DW, Grundy SM, Howard BV. Isopropanol precipitation method for the determination of apolipoprotein B specific activity and plasma concentrations during metabolic studies of very low density lipoprotein and low density lipoprotein apolipoprotein B. J Lipid Res. 1983;24:1261-1267.
41. Adeli K. Regulated intracellular degradation of apolipoprotein B in semi-permeable HepG2 cells. J Biol Chem. 1994;269:9166-9175.
42. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685.
43. Ginsberg HN. Role of lipid synthesis, chaperone proteins and proteasomes in the assembly and secretion of apoprotein B-containing lipoproteins from cultured liver cells. Clin Exp Pharmacol Physiol. 1997; 24:A29-A32.
44. Azrolan N, Breslow JL. A solution hybridization/RNase protection assay with riboprobes to determine absolute levels of apoB, A-I, and E mRNA in human hepatoma cell lines. J Lipid Res. 1990;31:1141-1146.
45. Tam S, Archer TK, Deeley RG. Effects of estrogen on apolipoprotein secretion by the human hepatocarcinoma cell line, HepG2. J Biol Chem. 1985;260:1670-1675.
46. Bocan TM, Mueller SB, Uhlendorf PD, Newton RS, Krause BR. Comparison of CI-976, an ACAT inhibitor, and selected lipid-lowering agents for antiatherosclerotic activity in iliac-femoral and thoracic aortic lesions. A biochemical, morphological, and morphometric evaluation. Arterioscler Thromb. 1991;11:1830-1843.
47. Krause BR, Anderson MK, Bisgaier CL, Bocan TM. Bousley R, DeHart P, Essenburg A, Hamelehle KL, Homan R, Kieft K, McNally W, Stanfield R, Newton RS. In vivo evidence that the lipid-regulating activity of the ACAT inhibitor CI-976 in rats is due to inhibition of both intestinal and liver ACAT. J Lipid Res. 1993;34:279-294.
48. Heider JG, Pickens CE, Kelly LA. Role of acyl CoA:cholesterol acyltransferase in cholesterol absorption and its inhibition by 57-118 in the rabbit. J Lipid Res. 1983;24:1127-1134.
49. Ooyen C, Zecca A, Zanelli T, Catapano AL. Decreased intracellular degradation and increased secretion of apoB-100 in HepG2 cells after inhibition of cholesteryl ester synthesis. Atherosclerosis. 1997;130: 143-152.
50. Wu X, Shang A, Jiang H, Ginsberg HN. Low rates of apoB secretion from HepG2 cells result from reduced delivery of newly synthesized triglyceride to a "secretion-coupled" pool. J Lipid Res. 1996;37:1198-1206.
51. Bostrom K, Wettesten M, Boren J, Bondjers G, Wiklund O, Olofsson S. Pulse-chase studies of the synthesis and intracellular transport of apolipoprotein B-100 in HepG2 cells. J Biol Chem. 1986;261:13800-13806.
52. Yeung SJ, Chen SH, Chan L. Ubiquitin-proteasome pathway mediates intracellular degradation of apolipoprotein B. Biochemistry. 1996;35: 843-848.
53. Fisher EA, Zhou M, Mitchell DM, Wu X, Omura S, Wang H, Goldberg AL, Ginsberg HN. The degradation of apolipoprotein B100 is mediated by the ubiquitin-proteasome pathway and involves heat shock protein 70. J Biol Chem. 1997;272:20427-20434.
54. Wu XJ, Sakata N, Lele KM, Zhou MY, Jiang HS, Ginsberg HN. A two-site model for apoB degradation in HepG2 cells. J Biol Chem. 1997;272:11575-11580.
55. Adeli K, Mohammadi A, Macri J. Apolipoprotein B100 is associated with an ER60-like protease in HepG2 cells: the role of ER60 in intracellular degradation of apolipoprotein B. Circulation. 1996;94: I-149. Abstract.
56. Graham A, Wood JL, Russell LJ. Cholesterol esterification is not essential for secretion of lipoprotein components by HepG2 cells. Biochim Biophys Acta. 1996;1302:46-54.
57. Mohammadi A, Macri J, Newton S, Romain T, Dulay D, Adeli K. Effect of atorvastatin on intracellular stability and secretion of apolipoprotein B in HepG2 cells. Arterioscler Thromb Vasc Biol. 1998;18:783-793.
58. Wetterau JR, Aggerbeck LP, Bouma M, Eisenberg C, Munck A, Hermier M, Schmitz J, Gay G, Rader DJ, Richard GE. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science. 1992;258:999-1001.
59. Jamil H, Dickson Jr JK, Chu C, Lago MW, Rinehart JK, Biller SA, Gregg RE, Wetterau JR. Microsomal triglyceride transfer protein: specificity of lipid binding and transport. J Biol Chem. 1995;270:6549-6554.
60. Wang S, McLeod RS, Gordon DA, Yao Z. The microsomal triglyceride transfer protein facilitates assembly and secretion of apolipoprotein B-containing lipoproteins and decreases cotranslational degradation of apolipoprotein B in transfected COS-7 cells. J Biol Chem. 1996;271: 14124-14133.
61. Du EZ, Wang S, Kayden HJ, Sokol R, Curtiss LK, Davis RA. Translocation of apolipoprotein B across the endoplasmic reticulum is blocked in abetalipoproteinemia. J Lipid Res. 1996;37:1309-1315.
62. Hainer JW, Terry JG, Connell JM, Zyruk H, Jenkins RM, Shand DL, Gillies PG, Livak KJ, Hunt TL, Crouse JR. Effect of the acyl-CoA:cholesterol acyltransferase inhibitor DuP128 on cholesterol absorption and serum cholesterol in humans. Clin Pharmacol Ther. 1994;56:65-74.
63. Maduskuie TP, Wilde RG, Billheimer JT, Cromley DA, Germain S, Gillies PJ, Higley CA, Johnson AL, Penev P, Shimshick EJ, Wexler RR. Design, synthesis, and structure-activity relationship studies for a new imidazole series of J774 macrophage specific acyl-CoA:cholesterol acyltransferase (ACAT) inhibitors. J Med Chem. 1995;38:1067-1083.
64. Bilheimer DW, Cromley DA, Higley CA, Wexler RR, Robinson CS, Gillies PJ. The diarylthioimidazole, DuP 128, is a potent inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT). Ninth International Symposium on Atherosclerosis. 1991;184:A94. Abstract.
65. Gibbons GF, Khurana R, Odwell A, Seelaender MCL. Lipid balance in HepG2 cells: active synthesis and impaired mobilization. J Lipid Res. 1994;35:1801-1808.
66. Thrift RN, Forte TM, Cahoon BE, Shore VG. Characterization of lipoproteins produced by the human liver cell line, HepG2, under defined conditions. J Lipid Res. 1986;27:236-250.